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Abstract
On-going airway inflammation is characteristic for the pathophysiology of chronic obstructive pulmonary disease (COPD).
However, the key factors determining the decrease in lung function, an important clinical parameter of COPD, are not clear.
Genome-wide linkage analyses provide evidence for significant linkage to airway obstruction susceptibility loci on
chromosome 8p23, the location of the human defensin gene cluster. Moreover, a genetic variation in the defensin beta 1
(DEFB1) gene was found to be associated with COPD. Therefore, we hypothesized that DEFB1 is differently regulated and
expressed in human lungs during COPD progression. Gene expression of DEFB1 was assessed in bronchial epithelium and
BAL fluid cells of healthy controls and patients with COPD and using bisulfite sequencing and ChIP analysis, the epigenetic
control of DEFB1 mRNA expression was investigated. We can demonstrate that DEFB1 mRNA expression was significantly
increased in bronchopulmonary specimen of patients with COPD (n=34) vs. healthy controls (n=10) (p,0.0001).
Furthermore, a significant correlation could be detected between DEFB1 and functional parameters such as FEV1
(p=0.0024) and the FEV1/VC ratio (p=0.0005). Upregulation of DEFB1 mRNA was paralleled by changes in HDAC1-3, HDAC5
and HDAC8 mRNA expression. Whereas bisulfite sequencing revealed no differences in the methylation state of DEFB1
promoter between patients with COPD and controls, ChIP analysis showed that enhanced DEFB1 mRNA expression was
associated with the establishment of an active histone code. Thus, expression of human DEFB1 is upregulated and related
to the decrease in pulmonary function in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
inflammatory disorder influenced by environmental factors (espe-
cially cigarette smoking) and multiple genes. COPD is a leading
cause of morbidity and mortality worldwide [1]. The clinical course
of patients with COPD is closely related to the progression of
pulmonary inflammation and the decline in lung function, which is
an important clinical parameter of the disease. Genome-wide
linkage analyses in the Boston Early-Onset COPD study have
provided significant evidence for linkage of airway obstruction to
chromosome 8 [2] and, in particular, for forced expiratory volume
in 1 second (FEV1) to the region 23 of chromosome 8p [3].
Interestingly,themajorhumanbeta-defensingenecluster,including
human beta defensin 1 (DEFB1), maps to the same region [4].
Moreover, a genetic variation identified in exon 2 of DEFB1 was
found to be associated with COPD [5]. DEFB1 is an essential
component of the human epithelia against invading pathogens and
acts as an effector molecule of the host innate defense in the lung
[6,7]. However, little is known about specific components of the
innate immune system that play a role in the progression of COPD.
We hypothesized that DEFB1 is differently regulated and expressed
in the lung during progression of COPD.
DEFB1 maps to the chromosome 8p23.2-p23.1 and consists of
two relatively small exons and an intron [8]. The first 128-bp exon
encodes the signal sequence und propiece peptide; the second 234-
bp exon encodes the mature peptide. DEFB1 is expressed
constitutively in the airway epithelia and is not induced by
inflammatory mediators or bacterial products [9]. It is able to kill
or inactivate Gram-negative bacteria and fungi at micromolar
concentrations through direct contact with microorganisms or
indirectly by triggering innate and adaptive immune responses
[10,11]. DEFB1 is chemoattractive for immature dendritic cells
and memory T-cells through the CCR6 chemokine receptor
activation [12]. Because DEFB1 is believed to act as a baseline
defense molecule in the absence of infection and inflammation, we
focused on the role of epigenetic changes in regulation of DEFB1
gene expression. These changes include the DNA methylation
state or modifications of the core histones, such as methylation and
acetylation of specific residues of their N-terminal tails, which
directly affect gene transcription [13,14,15]. A positive correlation
has also been published between the disease severity and the
reduction in histone deacetylase (HDAC) activity in the peripheral
lung tissue of COPD patients [16]. Finally, the importance of
DEFB1 in both, innate and adaptive immunity as well as its
location on chromosome 8p23, where a significant evidence of
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21898linkagetoCOPD-relatedtraitshasbeenreported,makesDEFB1 an
interesting candidate for the association with COPD progression.
Methods
Ethics statement
This study was approved by the Ethic Committee of the
Medical Faculty of the University of Lu ¨beck; Germany. All study
participants provided written informed consent for the collection
of bronchial epithelial cell biopsies and bronchoalveolar lavage
(BAL) fluids.
Patients
Healthy volunteer controls and patients with COPD with
GOLD [1] stages 1–4 were recruited at the Medical Clinic of
the Research Center Borstel, Germany. Following written
informed consent bronchoscopy was performed according to
national guidelines [17] obtaining epithelial cell biopsies from
the middle lobe carina and BAL fluid with 200–300 ml of
normal saline.
BAL fluid and biopsy specimens were collected from ten
healthy subjects, two patients with mild COPD (stage 1), 13
patients with moderate COPD (stage 2), 15 patients with severe
COPD (stage 3) and four patients with very severe COPD (stage
4). Healthy subjects for bronchoscopy were volunteers with
FEV1/VC .70% of the predicted value and no signs or
symptoms of COPD recruited by advertisement. Chronic illnesses
(e.g. diabetes mellitus, renal insufficiency, HIV-infection) were
exclusion criteria for study participant. Bodyplethysmography was
performed using Jaeger MasterScreen 601045. The 6-min walking
test (6MWD), arterial blood gas analysis, assessment of the MRC
dypnoea scale and calculation of probability of survival based on
BODE score [18] completed the clinical investigations. Acute
exacerbations of COPD were defined according to the Anthoni-
sen criteria [19].
BAL fluid and bronchial epithelial cell biopsies
preparation
BAL fluid cells were centrifuged (at 500 xg for 10 min, 4uC) and
washed twice with PBS (at 500 xg for 5 min, 4uC). Cell viability
was assessed with the use of the trypan-blue exclusion method.
Bronchial epithelial cell biopsy specimens (two pieces from each
study participant) were homogenized with the use of the Pellet
Pestle Cordless Motor (Kontes, New Jersey, USA).
Real-time quantitative PCR
Total RNA was isolated with the Absolutely RNA kit
(Stratagene, La Jolla, CA, USA). Reverse transcription was
performed in the presence of Superscript III Reverse Transcrip-
tase (Invitrogen, Carlsbad, CA, USA). Gene transcript levels of
defensin, beta 1 (DEFB1) and housekeeping gene b2-microglobulin
(b2-M) were quantified by Real-time PCR with the use of
LightCycler Fast Start DNA MasterPlus SYBR Green Master
on a LightCycler 2.0 Instrument (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s instruc-
tions. Standard curves were obtained for each primer set with
serial dilutions of plasmid DNA containing the amplification
product. Absolute transcript levels are shown per one transcript of
b2-M or as a common logarithm of this ratio. Sequences of the
used primer sets were: DEFB1: sense 59-TGTCTGA-
GATGGCCTCAGGT-39, antisense 59-GGGCAGGCAGAATA-
GAGACA-39; b2-M: sense 59-GCTGTGCTCGCGCTACTCT-
C-39, antisense 59-GCGGCATCTTCAAACCTCCAT-39. Gene
transcript levels of histone deacetylases (HDACs) 1-11 were
quantified by Real-time PCR with the use of LightCycler 480
Probes Master and the universal probes #5 (HDAC2), #3
(HDAC3) and #58 (HDAC6) or LightCycler 480 SYBR Green I
Master (HDAC1, 4, 5, 7–11) on a LightCycler 480 Instrument
(Roche Applied Science, Mannheim, Germany). Variations of
transcript levels between different samples were corrected by b2-M
expression. Sequences of the primer sets used were: HDAC1: sense
59-CCAAGTACCACAGCGATGAC-39, antisense 59-TGGACA-
GTCCTCACCAACG-39; HDAC2: sense 59- TGAAGGAGAA-
GGAGGTCGAA-39, antisense 59- GGATTTATCTTCTTCCT-
TAACGTCTG -39; HDAC3: sense 59-CACCATGCCAAGAA-
GTTTGA-39, antisense 59-CCCGAGGGTGGTACTTGAG-39;
HDAC4: sense 59-GTGGTAGAGCTGGTCTTCAAGG-39, an-
tisense 59-GACCACAGCAAAGCCATTC-39; HDAC5: sense 59-
TCTGAATACCACACCCTGCTC-39, antisense 59-ACAAGG-
CAGCACAGCATACA-39; HDAC6: sense 59-AGTTCACCTT-
CGACCAGGAC-39, antisense 59-GCCAGAACCTACCCTGC-
TC-39; HDAC7: sense 59-CATGACCTCACAGCCATCTG-39,
antisense 59-CATTGAGGTTGGGGTTTCTG-39; HDAC8:
sense 59-CAGGATGGCATACAAGATGAAA-39, antisense 59-
ATGGGATCCCCAGCTATTGT-39; HDAC9: sense 59-ATCC-
CAAGCTCTGGTACACG-39, antisense 59-TCTTGTGCTCC-
TGGTAATGTGT-39; HDAC10: sense 59-CTGTCAACCTG-
CCCTGGA-39, antisense 59-CAGCTCAGGGTCAAACTCAA-
39; HDAC11: sense 59-TGTCTACAACCGCCACATCT-39,
antisense 59-TGTTCCTCTCCACCTTATCCA-39.
Chromatin immunoprecipitation assay (ChIP)
Approximately 1.5610
7 BAL fluid cells from COPD patients
and healthy controls at different clinical stages were washed twice
with PBS and cross-linked for 10 min with 1% formaldehyde in
serum-free medium at 37uC. Cross-linking was stopped with 1.25
M glycine. The following steps were carried out as previously
described [20]. The following antibodies were used: 10 mlo f
polyclonal rabbit anti-dimethyl-Histone H3 (Lys9) and 10 mgo f
rabbit monoclonal Anti-trimethyl-Histone H3 (Lys4) (#07-712
and #05-745, respectively, Millipore (Billerica, MA, USA); 10 ml
of polyclonal rabbit Anti-trimethyl-Histone H3 (Lys9) and Anti-
trimethyl-Histone H4 (Lys20). Negative control was included
omitting the antibody. The primer sets used for amplification
were: DEFB1 (region I): sense 59-CCACACTGGGGGCTCAC-
TTTCT-39, antisense 59-TGGCCAAGGCTACCTTCTCA-39;
DEFB1 (region II): sense 59-GAAGAGGGTGAAGTTTGAG-39,
antisense 59-AGGCAGTTCACACTGGA-39; DEFB1 (region
III): sense 59-AGAACTGCCTAACCTAGAAA-39, antisense 59-
ACTTCTAATCGCTAACCCCT-39; DEFB1 (region IV): sense
59-GGTTAGCGATTAGAAGTTC-39, antisense 59-TGGAGC-
GTCACTGTATT-39; DEFB1 (region V): sense 59-GCAATC-
CACCAGTCTTAT-39, antisense 59-AGGCAACACTCAGGA-
TT-39; DEFB1 (region VI): sense 59-GAGAACTTCCTACCTT-
CTGC-39, antisense 59-AGCCATCCGAGACTCAC-39; DEFB1
(region VII): sense 59-TGCCATAAGCACATTGC-39, antisense
59-GCCGAGAATAGCCAAGA-39; DEFB1 (region VIII): sense
59-CAATGTCTCTATTCTGCCT-39, antisense 59-TTCACTT-
CTGCGTCATT-39; LINE-1: sense 59-GCAGGCCTGGTGGT-
GAC-39, antisense 59-GCAGGCCTGGTGGTGAC-39; Histone
4 : sense 59-CATCACCAAGCCTGCCATTCGG-39, antisense
59-CACATCCATGGCTGTGACGGTC-39. The fraction of
immunoprecipitated DNA was determined by calculating of ratio
of DNA present in the precipitates compared with the DNA in the
input chromatin. Results were corrected by subtracting values of
control reaction performed without antibodies and normalization
on values of LINE-1 or Histone 4.
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Genomic DNA was purified from epithelial cell biopsy
specimens obtained from five healthy controls und five COPD
patients with the Easy-DNA Kit (Invitrogen, Carlsbad, CA, USA).
1 mg of genomic DNA was bisulfite converted using the EpiTect
Bisulfite Kit (Qiagen, Hilden, Germany) according to manufac-
turer’s instruction. Bisulfite-modified DNA was eluted with 20 ml
of TE buffer and amplified with AccuPrime Taq DNA Polymerase
High Fidelity (Invitrogen, Carlsbad, CA, USA) under the following
conditions: 2 min at 94uC; followed by 35 cycles of 94uC for
30 sec, 55uC for 30 sec, 68uC for 60 sec; and a final extension of
68uC for 10 min. Bisulfite specific primers were designed by
‘‘BiSearch’’ (http://bisearch.enzim.hu/?m=search). Sequences of
the primer sets used were: DEFB1 (Region 1, contained promoter
region): sense 59-TTTAGTGGGAAAAGAGAAAAGTT-39, an-
tisense 59-AACTAATAAATTACACAACCTC-39; DEFB1 (Re-
gion 2, contained exon 2 region): sense 59-GGGTTAATTT-
TTTGGAAGAGAA-39, antisense 59-CACAAAATTCATTT-
TAACCC-39. The PCR products were cloned into the pCR4-
TOPO vector with the TOPO TA Cloning Kit for Sequencing
using the TOP10 One Shot Chemically Competent cells
(Invitrogen, Carlsbad, CA, USA) and 10–11 clones from each
biopsy specimen were sequenced with T3 and T7 primer sets by
GATC Biotech (Konstanz, Germany). Methylation analysis has
been carried out with the MethTools software (http://genome.
imbjena.de/methtools/).
Statistical analysis
Results are expressed as mean 6 SD, mean 6 SEM or median
695% confidence interval. The one-tailed hypothesis was tested
using unpaired t-test from log transformed data. Non-normal
distributed values were tested with Mann-Whitney test. Analysis of
variance of three or more unmatched groups was performed with
the use of the One-way ANOVA test followed by Tukey’s Multiple
Comparison test or nonparametric Kruskal-Wallis test. When the
results were significant, the unpaired t-test or Mann-Whitney test,
respectively, was performed for comparison between groups.
Correlation analyses were performed with the use of Pearson
correlation in normal distributed values and Spearman nonpara-
metric correlation. Statistics were performed with GraphPad
Prism 5.02 software (GraphPad, San Diego, CA, USA) with
differences *p,0.05, **p,0.01 and ***p,0.001 considered
significant.
Results
DEFB1 mRNA expression is elevated in COPD and
associated with functional lung parameters
The basic characteristics of the 34 patients with COPD with
stages 1–4 and 10 healthy controls are shown in Table 1. Detailed
characteristics of all study participants are summarized in
supporting information, Table S1.
Absolute transcript levels of DEFB1 mRNA, normalized to the
amount of b2-M, were higher in samples of bronchial epithelial cell
biopsy from patients with COPD compared to the healthy controls
(p,0.0001). There was a significant association between DEFB1
mRNA expression and samples with increasing severity of COPD
(p=0.0014 for patients with stage 1 and 2; p,0.0001 for patients
with stage 3 and 4, Figure 1A). Furthermore, the increased DEFB1
mRNA expression significantly correlated with FEV1 (r=20.43,
p=0.0024) and the FEV1/VC ratio (r=20.49, p=0.0005,
Figure 1B). Significant correlation was also seen between DEFB1
mRNA and the ratios RV/TLC (r=0.54, p=0.0001) and IC/
TLC (r=20.50, p=0.0004), ITGV (r=0.48, p=0.0006), MEF50
(r=2058, p,0.0001) and pAO2 (r=20.50, p=0.0004) when all
subjects were included (Figure 1C). IC/TLC describes hyperin-
flation of the lung and is considered as an independent predictor of
mortality [21]. However, there was no significant correlation of
DEFB1 mRNA expression with pack years (r=0.28, p=0.1051),
CRP level (r=0.03, p=0.8587) or BODE score (r=0.05,
p=0.7727)(Table 2). By contrast, there was no difference in the
level of DEFB4 mRNA among the groups of patients with COPD
and healthy controls as the expression of DEFB4 mRNA was not
correlated with increasing clinical severity of disease (p=0.1716
for patients with stage 1 and 2; p=0.2372 for patients with stage 3
and 4, compared to healthy controls; Supporting information,
Figure S1). Furthermore, DEFB4 mRNA expression did not
correlate with clinical parameters of COPD including airway
obstruction, cigarette smoking and other lung function tests in the
Pearson correlation analysis. These data are summarized in
Table 2.
HDAC1 mRNA level is elevated in COPD and correlates
with DEFB1 mRNA expression
Since HDACs were also implicated in COPD [16], we next
analysed whether the increased DEFB1 mRNA expression in
patients with COPD was associated with the expression levels of the
eleven human HDAC isoforms (HDAC1-11) in bronchial epithelial
cell biopsies.The relativeexpressionofHDAC1mRNA normalized
to b2-M was increased in samples from patients with COPD, as
compared with samples from healthy controls (p=0.0428)
(Figure 2A). There were no significant differences between the
mRNA expression of HDAC2-11 in samples from patients with
COPD and those from healthy controls (supporting information,
Figure S2A). Despite higher levels of HDAC1 mRNA in biopsies of
patients with COPD, there was no significant correlation between
the HDAC1 mRNA expression and the airway obstruction, as
measured by the FEV1 (r=20.13, p=0.2185) and the FEV1/VC
ratio (r=20.20, p=0.1118)(supporting information, Figure S2B).
However, there was a positive correlation between the mRNA
expression of DEFB1 and HDAC1-3 and 8 as well as a negative
correlation between the DEFB1 and HDAC5 mRNA expressions
when all subjects were included (Figure 2B).
DNA methylation does not control DEFB1 mRNA
expression level
To see whether DNA methylation plays a role in the regulation
of DEFB1 transcription in bronchial biopsies of patients with
COPD we compared the extent of methylation of individual CpG
sites at the DEFB1 locus to samples from healthy controls. Because
the upstream part of the DEFB1 promoter (2700 bp) and whole
DEFB1 gene sequence (+1t o+7324 bp) did not meet the criteria
of a CpG island (length $200 bp, GC content $50% and obsCpG/
expCpG $0.6) [22], the upstream part the DEFB1 promoter with
eight CpG sites (region 1) and the downstream part of intron and
exon 2 of DEFB1 with seven CpG sites (region 2) were analysed by
sodium bisulfite sequencing (Figure 3A). At least 10 individual
sequences (clones) were sequenced and analysed per patient with
COPD and healthy control (Figure 3B). Each sequence (clone) is
represented by a row and clones from the same subject are
grouped. The individual CpG sites of the DEFB1 promoter and
intron/exon 2 are arrayed in columns. Filled circles indicate
methylated CpG sites, while open circles indicate unmethylated
sites. Bisulfite sequencing revealed no differences in the magnitude
of the methylation between the two groups at each CpG site
despite the significant differences in the levels of DEFB1 mRNA
(p=0.0079) between samples from these two groups (Figure 3C).
DEFB1 Gene Expression in COPD
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Characteristic Healthy controls COPD
Stage 1 Stage 2 Stage 3 Stage 4
Number 10 2 13 15 4
Age [years] 31.367.8 73.567.8 66.969.9 66.467.5 58.363.6
(20–46) (68–79) (52–82) (46–77) (55–63)
Sex [M/F] 3/7 1/1 9/4 10/5 2/2
BMI 22.761.9 27.260.2 28.3–5.8 25.464.7 21.363.7
(20.0–26.7) (27.0–27.3) (22.5–44.6) (16.0–35.5) (16.2–24.5)
Pack years 2.962.8 50.0614.1 41.9619.3 39.7616.6 42.5618.9
(1–7) (40–60) (10–85) (5–65) (30–70)
6MWD [m] 516.0649.3 305.06169.7 352.36127.1 291.06122.3 367.5688.6
(430–625) (185–425) (150–545) (0–465) (240–430)
FEV1 [%] 104.2616.6 89.962.0 63.9610.2 38.266.2 26.162.8
(60.7–117.4) (88.5–91.3) (50.1–79.4) (30.2–47.3) (22.8–29.0)
VC [%] 108.5–26.4 107.362.3 86.3612.4 69.2614.7 61.3610.6
(54.4–160.9) (105.7–108.9) (65.2–108.9) (42.6–97.7) (52.8–76.3)
FEV1/VC [%] 88.768.6 73.1611.2 65.6612.6 46.8610.3 39.167.5
(73.5–101.5) (65.2–81.0) (49.5–90.7) (30.0–66.3) (31.5–46.3)
BODE score { 2.062.8 2.262.3 5.162.1 6.361.0
(0.0–4.0) (0.0–6.0) (2.0–9.0) (5.0–7.0)
Data are presented as mean6Std (range), COPD: chronic obstructive pulmonary disease, M: male, F: female, BMI: body mass index, pack years: the number of cigarettes
smoked per day x number of years smoked)/20 (1 pack has 20 cigarettes), 6MWD: 6-minutes walking distance, FEV1: forced expiratory volume in one second, VC: vital
capacity, BODE score: index, which incorporate body mass index, airflow obstruction, dyspnoea and exercise capacity
18, % of predicted value, { not determined. Stages
1 through 4 denote severity of disease according to the Deutsche Atemwegsliga and the Deutsche Gesellschaft fu ¨r Pneumologie und Beatmungsmedizin
27, with higher
number indicating greater severity. (Additional characteristics of all study participants are summarized in Table S1 in the supporting information).
doi:10.1371/journal.pone.0021898.t001
Figure 1. DEFB1 mRNA expression analysis in bronchial epithelial cell biopsies from patients with COPD and healthy controls. (A)
Expression levels of DEFB1 mRNA in epithelial cell biopsies from patients with COPD (N=34 total, N=15 for COPD 1+2, N=19 for COPD 3+4) and
healthy controls (N=10). Levels of DEFB1 mRNA were quantified by Real-time PCR, variations of transcript levels were corrected by b2-M mRNA levels
and log transformed for statistical analysis. Differences between COPD patients (total) and healthy controls were tested using unpaired t-test. Analysis
of variance of three groups was performed with the use of the One-way ANOVA test followed by Tukey’s Multiple Comparison test. When the results
were significant, the unpaired t-test was performed for comparison between the groups with differences p,0.05 considered significant. Results are
presented as mean6SEM, each symbol represents a single sample. (B) Correlations between levels of DEFB1 mRNA and FEV1 and the ratio FEV1/VC
and (C) correlations between levels of DEFB1 mRNA and the ratios RV/TLC, IC/TLC, ITGV and MEF50 in epithelial cell biopsies from patients with COPD
(N=34) and healthy controls (N=10). Analyses in (B) and (C) were performed using Pearson correlations with differences p,0.05 considered
significant. Each symbol represents a single sample. (The complete data and p values are given in supporting information, Table 2).
doi:10.1371/journal.pone.0021898.g001
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with DEFB1 mRNA expression level
The results described above showed that DEFB1 mRNA
expression is upregulated in bronchial epithelial cell biopsies of
patients with COPD and correlates with pathological changes
characteristic for COPD. Since differences in the methylation state
of the DEFB1 promoter between patients with COPD and healthy
controls were not detected, we wanted to analyze if other
epigenetic marks were associated with the increased DEFB1
mRNA expression. Since material from bronchial epithelial cell
biopsies was not sufficiently available to perform chromatin
immunoprecipitation assays (ChIP), cells obtained from BAL fluid
from patients with COPD and healthy controls were used. Levels
of the DEFB1 mRNA in BAL fluid cells obtained from patients
Table 2. Correlation analysis of DEFB1 and DEFB4 mRNA expression.
Parameter DEFB1 mRNA expression DEFB4 mRNA expression
Pearson r P value Pearson r P value
FEV1 [l] 20.52 0.0002 20.20 0.2174
FEV1 [% predicted] 20.43 0.0024 20.12 0.4629
VC [% predicted] 20.29 0.0338 20.27 0.0920
FEV1/VC [% predicted] 20.49 0.0005 0.00 0.9887
FEV1/FVC [l] 20.54 0.0001 20.03 0.8784
IC/TLC [l] 20.50 0.0004 20.20 0.2045
RV/TLC [l] 0.54 0.0001 0.28 0.0774
ITGV [% predicted] 0.48 0.0006 20.04 0.7832
MEF50 [% predicted] 20.58 ,0.0001 20.20 0.2097
pack years 0.28 0.1051 0.20 0.2449
BODE score 0.05 0.7727 0.20 0.2861
SGRQ 0.32 0.1760 20.10 0.6995
CRP [mg/dl] 0.03 0.8587 20.04 0.8332
pAO2 [mm Hg] 20.50 0.0004 20.09 0.5775
DEFB1: defensin, beta 1, DEFB4: defensin, beta 4, FEV1: forced expiratory volume in one second, VC: vital capacity, FVC: forced vital capacity, IC: inspiratory capacity, RV:
residual volume, TLC: total lung capacity, ITGV: intrathoracic gas volume, MEF50: maximal expiratory flow at 50%, pack years: the number of cigarettes smoked per day x
number of years smoked)/20 (1 pack has 20 cigarettes), BODE score: index, which incorporates body mass index, FEV1, MRC dyspnoea scale and 6MWD
18,S G R Q :S t
George’s Respiratory Questionnaire, CRP: c-reactive protein, paO2: arterial oxygen tension.
doi:10.1371/journal.pone.0021898.t002
Figure 2. HDAC mRNA expression analysis in bronchial epithelial cell biopsies from patients with COPD and healthy controls. (A)
Expression levels of HDAC1 mRNA in epithelial cell biopsies from patients with COPD (N=34) and healthy controls (N=10). Levels of HDAC1 mRNA
were quantified by Real-time PCR, variations of transcript levels were corrected by b2-M mRNA levels and log transformed for statistical analysis.
Analysis of variance between patients with COPD and healthy controls was performed by the use of the unpaired t-test with differences p,0.05
considered significant. Results are presented as mean6SEM, each symbol represents a single sample. (B) Correlations between levels of HDAC1
mRNA and HDAC1-3, 5 and 8 mRNA in epithelial cell biopsies from patients with COPD (N=34) and healthy controls (N=10). Analysis was performed
using Pearson correlations with differences p,0.05 considered significant. Each symbol represents a single sample. (The complete data and p values
are given in supporting information, Figures S2 and S3).
doi:10.1371/journal.pone.0021898.g002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21898Figure 3. Bisulfite sequencing analysis of CpG methylation in bronchial epithelial cell biopsies. (A) Schematic view of the DEFB1 gene
(NCBI GeneID: 1672) with exons displayed as filled boxes; the transcriptional start site is indicated; coding sequences are marked in black and 59-UTR is
shown in gray. Vertical arrows represent locations of eight CpG sites on the DEFB1 promoter (region 1) relative to the transcriptional start site and seven
CpG sites on the DEFB1 downstream part of intron and exon 2 (region 2). (B) Bisulfite sequencing analysis of CpG methylation in bronchial epithelial cell
biopsies of patients with COPD and healthy controls (both, N=5 for region 1, N=2 for region 2). Genomic DNA was treated as described, amplified by
PCR and cloned for sequencing. At least 10 individual sequences (clones) were sequenced and analyzed per study subject. Each sequence (clone) is
represented by a row and clones from the same subject are grouped. The individual CpG sites are arrayed in columns. Filled circles indicate methylated
CpG; open circles indicate unmethylated CpG. (C) Average percentage of methylation for each CpG site of region 1 and levels of the corresponding
DEFB1 mRNA expression for patients with COPD (N=5, gray bars) and healthy controls (N=5, black bars). Results are presented as mean6SEM.
doi:10.1371/journal.pone.0021898.g003
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to the analysis of variance (p=0.3903), when compared with the
levels in samples from healthy controls. However, there was a high
degree of variation in DEFB1 mRNA expression for all subjects, in
particular in patients with COPD (Figure 4A). Thus, the samples
were used to analyze the histone modification pattern changes on
the basis of the expression level of DEFB1 mRNA, but regardless
of their COPD status. We selected four upstream regions located
from 2665 to 287 relative to the transcriptional start site (regions
I to IV) and several regions throughout the DEFB1 loci from
2123 to +7205 bp (regions V to VIII) (Figure 4B). Histone H3
lysine 4 trimethylation (H3K4me3) as an indicator for an active
chromatin state was analysed in chromatin from BAL fluid cells by
ChIP (N=11) and then correlated with corresponding levels of the
DEFB1 mRNA. With the exception of the promoter region III
(r=0.27, p=0.4483) and region VIII within exon 2 (r=0.19,
p=0.6007), the overall levels of H3K4me3 were significantly
correlated with increasing levels of DEFB1 mRNA in the Pearson
correlation analysis (region I: r=0.83, p=0.0008; region II:
r=0.72, p=0.0096; region IV: r=0.84, p=0.0007; region V:
r=0.87, p=0.0002; region VI: r=0.90, p,0.0001; region VII:
r=0.77, p=0.0031) (Figure 4C).
Altogether, these results corroborate our hypothesis that DEFB1
is associated with the progression of COPD and provide a first
view on the epigenetic regulation of DEFB1 mRNA expression.
Discussion
Currently, the role of the specific components of the innate
immune system, especially defensins, and its clinical relevance in
diverse clinical phenomena of COPD has not been extensively
studied. COPD is a progressive inflammatory disease caused by
the interaction of genetic susceptibility and environmental
influences [23]. The human defensin beta 1(DEFB1) gene product,
an endogenous antimicrobial peptide found in the airway
epithelium [9], is believed to play an important role in mucosal
immunity of the lung [24]. Moreover, genetic variations of DEFB1
identified in the 1654 G/A locus in the DEFB1 exon 2 coding for a
valine to isoleucine substitution at position 38 (Val38Ile) and in the
668 C/G locus in 39 flank of DEFB1 mRNA were found to be
associated with COPD [5,25]. The function of DEFB1 within the
airway and its location on 8p, where evidence of linkage to
qualitative and quantitative COPD-related phenotypes has been
reported [2,26], makes DEFB1 an interesting candidate for
Figure 4. Analysis of histone H3 lysine 4 methylation (H3K4me3) within the DEFB1 locus in BAL fluid cells. (A) Expression levels of
DEFB1 mRNA in BAL fluid cells from patients with COPD (N=34) and healthy controls (N=10). Levels of DEFB1 mRNA were quantified by Real-time
PCR, variations of transcript levels were corrected by b2-M mRNA levels and log transformed for statistical analysis. Analysis of variance between
patients with COPD and healthy controls was performed by the use of the unpaired t-test with differences p,0.05 considered significant. Results are
presented as mean6SEM, each symbol represents a single sample. (B) Schematic view of the DEFB1 gene (NCBI GeneID: 1672) with exons displayed
as filled boxes; the transcriptional start site and location of PCR primer sets used in ChIP experiments are indicated; coding sequences are marked in
black and 59-UTR is shown in gray. (C) Correlations between levels of H3K4me3 and DEFB1 mRNA in BAL fluid cells from study participants (N=11)
regardless of their COPD status. Levels of H3K4me3 were analyzed by ChIP using specific antibodies and quantified by Real-time PCR. The ChIP values
are expressed as % of input corrected by subtracting values for no-antibody control and normalized on total histone H4. Correlations analysis was
performed using Pearson correlations with differences p,0.05 considered significant. Each symbol represents a single sample.
doi:10.1371/journal.pone.0021898.g004
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we now demonstrate that the gene expression of DEFB1 is
increased in samples of bronchial epithelial cell biopsy from
patients with COPD, as compared with expression in healthy
controls. Chronic airway obstruction, measured by reduction in
forced expiratory volume in one second (FEV1) and the ratio of
FEV1 to vital capacity or forced vital capacity (FEV1/VC and
FEV1/FVC, respectively) [1,27], is a cardinal feature of COPD.
Their values are associated with disease severity and progression.
For these quantitative phenotypes, our results provide an evidence
for linkage to the DEFB1 gene expression in bronchial epithelial
cell biopsies when all subjects were included. Interestingly, DEFB1
is located within the airway obstruction susceptibility loci on
chromosome 8p23 with significant evidence of linkage to FEV1
with the highest LOD score of 3.30 [3]. In addition to FEV1, VC,
FVC and the ratios FEV1/VC and FEV1/FVC, the analysis of
other lung function tests assessed by bodyplethysmography or
blood gas analysis gave similar results, suggesting that DEFB1 may
be involved in the progression of airway obstruction. Since IC/
TLC, describing hyperinflation of the lung, is considered as an
independent predictor of mortality [21], DEFB1 gene expression
may thus be identified as a novel genetic determinants of COPD-
related phenotypes and a potential predictive marker for the
outcome of COPD. However, despite the amplified support for
genetic association with COPD, to our current state of under-
standing about the pathophysiology of COPD DEFB1 is not an
obvious COPD susceptibility gene [28].
The DEFB1 gene (NCBI GenID: 1672) consists of two exons,
encoding several forms of gene products ranging from 36 to 47
amino acid residues and differing from each other by amino
terminal truncation [29]. For many years, the biochemical barrier
function against invading pathogens by disrupting their cytoplas-
mic membrane and killing and/or inactivating particular spectra
of bacteria and fungi was the major known role of DEFB1. Later
evidence has shown that DEFB1 gene products constitutively
produced by epithelial cells also display chemoattractant activity to
immune cells [12], whose upregulation and secretion may amplify
the immune response and contribute to airway inflammation seen
in COPD. The ability of DEFB1 to promote necrotic and/
or apoptotic cell death by increasing membrane permeability
followed by the release of cytochrome c and activation of caspases
[30,31] suggests that DEFB1 could also be involved in the airway
limitation and structural changes occurring in COPD. Finally, as
disruption of the balance between apoptosis and regeneration of
structural lung cells in the lung is reported to be important in the
progressive destruction of healthy lung tissue during COPD [32],
we speculate that DEFB1, the cytotoxic peptide abundantly
produced by the airway epithelial cells of patients with COPD,
may contribute to the apoptotic cell death within the conducting
airway epithelium, an important upstream event in the pathogen-
esis of COPD.
With respect to the possible mechanisms involved in the
regulation of DEFB1 in the airways of patients with COPD, the
methylation analysis of CpG sites within the DEFB1 promoter and
coding sequence showed no remarkable differences in the
methylation pattern when bronchial epithelial cell biopsies
obtained from patients with COPD were compared with biopsies
from healthy controls. These results strongly argue against an
important role of methylation of these CpG sites of the DEFB1
gene in the transcriptional regulation of DEFB1. Active histone
modifications including histone H3 lysine 4 trimethylation
(H3K4me3) are generally regarded as an indicator for active
chromatin transcription and localized almost exclusively around
the transcriptional start site [33,34,35]. Our ChIP experiments
showed that H3K4me3 is present throughout the DEFB1 gene
locus and, with exception of two positions within the promoter
(region III) and exon 2 (region VIII), the levels of H3K4me3
correlate with transcriptional activity of DEFB1. Because
H3K4me3 may well mark promoters and genes that became
activated and provide the epigenetic setting to facilitate such
activation [36], these results indicate that the establishment of such
an active epigenetic code could be sufficient to establish the
substantial induction of DEFB1 expression in the airways of
COPD patients. Furthermore, histone H3 lysine 9 di- and
trimethylation (H3K9me2 and H3K9me3) and histone H4 lysine
20 trimethylation (H4K20me3), which are generally correlated
with transcriptional repression [37,38,39,40], are present in
promoter and coding regions of DEFB1. However, with the
exception of the DEFB1 intron region VII and H3K9me3, the
levels of these histone marks do not correlate with DEFB1
transcriptional activity. Since these marks can be observed in both,
the repressive and active state [41,42,43], it seems likely that the
combinatorial presence of such bipartite histone modifications
may well represent the regulative event that seals transcriptional
activation.
A possible scenario for DEFB1 gene activation in patients
with COPD could also involve changes in histone deacetylases
(HDACs) because the progressive reduction in both, the activity
and expression of HDACs, especially HDAC2, in COPD has
already been shown [16]. There are eleven classic human
HDACs, HDAC1 to HDAC11, playing an essential role in gene
regulation [44,45]. In the present study we have shown that only
the level of HDAC1 was increased in samples of bronchial
epithelial cell biopsy from patients with COPD. In contrast to
Ito et al. [16], we could not find any reduction in the levels of
the HDAC2 mRNA previously reported in peripheral lung
tissues and alveolar macrophages from patients with COPD.
These discrepancies may be relatively specific to the different
sample types (cells or tissues) used in our and others experi-
ments. In addition, we found a positive correlation between
levels of the HDAC1 and DEFB1 mRNA. Moreover, levels of
the DEFB1 mRNA also positively correlated with expression of
HDAC2, 3 and 8 mRNA and inversely correlated with
expression of HDAC5 mRNA. These HDACs are also reported
to be reduced in lung tissues and macrophages from patients
with COPD in the above mentioned paper by Ito et al.
Currently, we do not know if HDAC1 or the other HDACs
directly positively affect DEFB1 mRNA expression. Although
histone deacetylation is generally correlated with gene repres-
sion due to its condensing effect on chromatin structure, a
number of publications point to the importance of rapid
acetylation turnover at transcriptionally active sites [46,47,48].
Based on our results and becaused i f f e r e n tH D A C sa p p e a rt ob e
involved in different cellular processes and presumable regulate
different sets of genes [49,50], we believe that these HDACs
provide a molecular basis for the increased DEFB1 expression in
the airways as COPD progresses.
Here we report that the expression of DEFB1 is increased in
bronchial epithelial cell biopsies of patients with COPD and
associated with pathological changes characteristic for COPD and
disease severity. Shift of the epigenetic marks within the DEFB1
gene locus and differentially expressed HDACs could have
contributed to such gene activation events in COPD. Thus,
further studies for DEFB1 and other molecules of the innate
immune system may lead to the identification of novel genetic
determinants in the development of COPD, which may lead to
better understanding of COPD pathophysiology and new
opportunities for prevention and treatment.
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Figure S1 DEFB4 mRNA expression in bronchial epithe-
lial cell biopsies from patients with COPD and healthy
controls. Expression levels of DEFB4 mRNA in epithelial cell
biopsies from patients with COPD (N=34 total, N=13 for COPD
1+2, N=18 for COPD3+4) and healthy controls (N=10). Levels of
DEFB4 mRNA were quantified by Real-time PCR, variations of
transcript levels were corrected by b2-M mRNA levels and log
transformed for statistical analysis. Differences between COPD
patients (total) and healthy controls were tested using unpaired t-
test. Analysis of variance ofthree groups was performed withthe use
of the One-way ANOVA test followed by Tukey’s Multiple
Comparison test. When the results were significant, the unpaired
t-test was performed for comparison between the groups with
differences p,0.05 considered significant. Results are presented as
mean6SEM, each symbol represents a single sample.
(PDF)
Figure S2 Histone deacetylase (HDAC) expression anal-
ysis in bronchial epithelial cell biopsies. (A) Expression
levels of HDAC1-11 mRNA in epithelial cell biopsies from COPD
patients (N=34) and healthy controls (N=10). Levels of HDAC
mRNA were quantified by Real-time PCR, variations of transcript
levels were corrected by b2-M mRNA levels and log transformed
for statistical analysis. Normal and non-normal distributed values
were tested using unpaired t-test und Mann-Whitney test,
respectively, with differences p,0.05 considered significant.
Results are presented as mean 6 SEM, each symbol represents
a single sample. (B) Correlations between levels of HDAC1
mRNA and FEV1 and the ratio FEV1/VC in epithelial cell
biopsies from COPD patients (N=34) and healthy controls
(N=10). Analysis was performed using Pearson correlation with
differences p,0.05 considered significant. Each symbol represents
a single sample.
(PDF)
Figure S3 Correlations between levels of HDACs und
DEFB1 mRNA in bronchial epithelial cell biopsies.
Correlations between transcript levels of HDAC1 to 11 mRNA
and DEFB1 mRNA in epithelial cell biopsies from COPD patients
(N=34) and healthy controls (N=10). Transcript levels of
HDACs mRNA were corrected by b2-M mRNA levels and log
transformed for statistical analysis. Normal and non-normal
distributed values were tested using Pearson and Spearman
correlation analysis, respectively, with differences p,0.05 consid-
ered significant. Each symbol represents a single sample.
(PDF)
Table S1 Detailed characteristics of the study partici-
pants (additional to Table 1). Data are presented as
mean6Std (range), COPD: chronic obstructive pulmonary
disease, FVC: forced vital capacity, FEV1: forced expiratory
volume in one second, PEF: peak expiratory flow, PIF: peak
inspiratory flow, VC: vital capacity, IC: inspiratory capacity, RV:
residual volume, TLC: total lung capacity, ITGV: intrathoracic
gas volume, SGRQ: St George’s Respiratory Questionnaire, CRP:
c-reactive protein, pAO2: arterial oxygen tension, pACO2: arterial
carbon dioxide tension, % of predicted value, { not determined.
Stages 1 through 4 denote severity of disease according to the
Deutsche Atemwegsliga and the Deutsche Gesellschaft fu ¨r
Pneumologie, with higher number indicating greater severity.
(PDF)
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